Form 4: aTyr Pharma CFO Acquires 275,000 Employee Stock Options
SEC Form 4 Filing
Jill Marie Broadfoot, CFO of aTyr Pharma, acquired 275,000 employee stock options on January 8, 2025, according to a Form 4 filing.
Summary
- Jill Marie Broadfoot, the Chief Financial Officer of aTyr Pharma Inc. (ATYR), acquired 275,000 employee stock options on January 8, 2025.
- The options have an exercise price of $3.74.
- The options vest in 48 equal monthly installments starting February 8, 2025, and will be fully exercisable by January 8, 2029.
- The options are subject to accelerated vesting upon termination without cause upon a change of control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it aligns the CFO's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of the transaction: CFO acquired 275,000 employee stock options. |
| 02/08/2025 | First vesting date: Options begin to vest in 48 equal monthly installments. |
| 01/08/2029 | Full vesting date: Options will be fully exercisable. |
| 01/10/2025 | Date of the Form 4 filing. |
| 01/08/2035 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.